Does Missouri Medicaid cover GLP-1s for weight loss?
Does Missouri Medicaid cover GLP-1s for weight loss?
Missouri Medicaid covers GLP-1 receptor agonists for obesity, subject to prior authorization. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". The published threshold is: 18 and over: 30 or more, or 27 or more with a documented weight-related comorbidity. 12–17: at or above the 95th percentile for age and sex. On what has to be tried or preferred first: Zepbound is the preferred obesity agent. Wegovy is non-preferred and not covered for weight reduction at all — only for cardiovascular risk. Mounjaro needs a written medical reason why Zepbound cannot be used. Those criteria are quoted from MO HealthNet GLP-1 Receptor Agonists for All Indications prior authorization form, read directly rather than summarized from an aggregator.
What the prior authorization asks for
- BMI threshold
- 18 and over: 30 or more, or 27 or more with a documented weight-related comorbidity. 12–17: at or above the 95th percentile for age and sex.
- Tried first
- Zepbound is the preferred obesity agent. Wegovy is non-preferred and not covered for weight reduction at all — only for cardiovascular risk. Mounjaro needs a written medical reason why Zepbound cannot be used.
Anyone already on Zepbound before MO HealthNet covered it has to produce the BMI at the start of therapy, the current BMI, how they were paying and the three most recent fill dates.
Both tools fill from these criteria rather than from a template — a prior authorization for Missouri, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.
Whatever Missouri decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.
If you end up paying cash
The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:
- Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
- Noom Med$249/moverified 2026-09-22compounded, not FDA approved
- Found$289/moverified 2026-09-22compounded, not FDA approved
Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.
The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.
Other states with criteria of their own
Source: MO HealthNet GLP-1 Receptor Agonists for All Indications prior authorization form , effective 2024-10-01. Read on 2026-09-10. Fee-for-service rules; a managed-care plan in Missouri can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.